BACKGROUND: Dopamine receptors (DRs) are members of seven transmembrane domain trimeric guanosine 5'-triphosphate (GTP)-binding protein-coupled receptor family. Through dopamine receptor activation, dopamine plays a significant role in regulating gene expression, such as induced tumor cell migration. MATERIALS AND METHODS: We investigated DRD1 and DRD2 expressions in patients with esophageal squamous cell carcinoma (ESCC) for immunohistochemistry and analyzed differences between DRD1, DRD2, and DARPP-32 expressions of clinicopathological features in 122 patients with ESCC. RESULTS: DRD1 immunostaining correlated with the pathologic grade (P = 0.0127), and DRD2 immunostaining correlated with the pathologic stage (P = 0.0432) and pN classification (P = 0.0112). A significant correlation was found between DRD1 and DRD2 expression (P = 0.0292). However, no correlation was observed between DRD1/DRD2 expression and DARPP-32 expression (P = 0.4555 and 0.4774, respectively). No correlation was observed between the DRD1/DRD2 expression and patient prognosis. To find the cooperative role between DRD1, DRD2, and DARPP-32 expressions, patients were classified into the different groups. In the DRD2/DARPP-32 combination, the (+/-) group was significantly correlated with pathologic stage (P = 0.0006), lymph node metastasis (P = 0.0001), pT (P = 0.0287), and tumor size (P = 0.0202). Moreover, patients with this combination showed a lower survival rate compared with the other three groups (P = 0.0287). CONCLUSIONS: We conclude that DRD2/DARPP-32 expression is associated with tumor progression and that DRD2/DARPP-32 expressions may help predict prognosis in patients with ESCC.
BACKGROUND:Dopamine receptors (DRs) are members of seven transmembrane domain trimeric guanosine 5'-triphosphate (GTP)-binding protein-coupled receptor family. Through dopamine receptor activation, dopamine plays a significant role in regulating gene expression, such as induced tumor cell migration. MATERIALS AND METHODS: We investigated DRD1 and DRD2 expressions in patients with esophageal squamous cell carcinoma (ESCC) for immunohistochemistry and analyzed differences between DRD1, DRD2, and DARPP-32 expressions of clinicopathological features in 122 patients with ESCC. RESULTS:DRD1 immunostaining correlated with the pathologic grade (P = 0.0127), and DRD2 immunostaining correlated with the pathologic stage (P = 0.0432) and pN classification (P = 0.0112). A significant correlation was found between DRD1 and DRD2 expression (P = 0.0292). However, no correlation was observed between DRD1/DRD2 expression and DARPP-32 expression (P = 0.4555 and 0.4774, respectively). No correlation was observed between the DRD1/DRD2 expression and patient prognosis. To find the cooperative role between DRD1, DRD2, and DARPP-32 expressions, patients were classified into the different groups. In the DRD2/DARPP-32 combination, the (+/-) group was significantly correlated with pathologic stage (P = 0.0006), lymph node metastasis (P = 0.0001), pT (P = 0.0287), and tumor size (P = 0.0202). Moreover, patients with this combination showed a lower survival rate compared with the other three groups (P = 0.0287). CONCLUSIONS: We conclude that DRD2/DARPP-32 expression is associated with tumor progression and that DRD2/DARPP-32 expressions may help predict prognosis in patients with ESCC.
Authors: Frank Entschladen; Kerstin Lang; Theodore L Drell; Jan Joseph; Kurt S Zaenker Journal: Cancer Immunol Immunother Date: 2002-07-27 Impact factor: 6.968
Authors: Rosario Pivonello; Diego Ferone; Wouter W de Herder; Johan M Kros; Maria Laura Del Basso De Caro; Marica Arvigo; Lucio Annunziato; Gaetano Lombardi; Annamaria Colao; Leo J Hofland; Steven W J Lamberts Journal: J Clin Endocrinol Metab Date: 2004-05 Impact factor: 5.958
Authors: R Böni; W Lichtensteiger; H C Steinert; R A Böni; H Früh; R Dummer; D G Hartmann; E Laine; G Burg Journal: Melanoma Res Date: 1997-04 Impact factor: 3.599
Authors: M Picardo; S Passi; M Nazzaro-Porro; A Breathnach; C Zompetta; A Faggioni; P Riley Journal: Biochem Pharmacol Date: 1987-02-15 Impact factor: 5.858
Authors: Y Ebihara; M Miyamoto; A Fukunaga; K Kato; T Shichinohe; Y Kawarada; T Kurokawa; Y Cho; S Murakami; H Uehara; H Kaneko; H Hashimoto; Y Murakami; T Itoh; S Okushiba; S Kondo; H Katoh Journal: Br J Cancer Date: 2004-07-05 Impact factor: 7.640
Authors: Jillian S Weissenrieder; Jeffrey D Neighbors; Richard B Mailman; Raymond J Hohl Journal: J Pharmacol Exp Ther Date: 2019-04-18 Impact factor: 4.030
Authors: Christian Hansen; Jillian Howlin; Anders Tengholm; Oleg Dyachok; Wolfgang F Vogel; Angus C Nairn; Paul Greengard; Tommy Andersson Journal: J Biol Chem Date: 2009-08-03 Impact factor: 5.157
Authors: Mark N Stein; Jyoti Malhotra; Rohinton S Tarapore; Usha Malhotra; Ann W Silk; Nancy Chan; Lorna Rodriguez; Joseph Aisner; Robert D Aiken; Tina Mayer; Bruce G Haffty; Jenna H Newman; Salvatore M Aspromonte; Praveen K Bommareddy; Ricardo Estupinian; Charles B Chesson; Evita T Sadimin; Shengguo Li; Daniel J Medina; Tracie Saunders; Melissa Frankel; Aparna Kareddula; Sherrie Damare; Elayne Wesolowsky; Christian Gabel; Wafik S El-Deiry; Varun V Prabhu; Joshua E Allen; Martin Stogniew; Wolfgang Oster; Joseph R Bertino; Steven K Libutti; Janice M Mehnert; Andrew Zloza Journal: J Immunother Cancer Date: 2019-05-22 Impact factor: 13.751